

**Amendments to the claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of claims:**

Claims 1-77 (canceled)

78. (New) An isolated peptide consisting of
- a) the amino acid sequence Val-Ala-Leu-Asn-Ser-Pro-Leu-Ser-Gly-Gly-Met-Arg-Gly-Ile-Arg-Gly-Ala-Asp-Phe-Gln-Cys-Phe-Gln-Gln-Ala-Arg-Ala-Val-Gly-Leu-Ala-Gly-Thr-Phe-Arg-Ala-Phe-Leu-Ser-Ser-Arg-Leu-Gln-Asp-Leu-Tyr-Ser-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Ile-Val-Asn-Leu-Lys-Asp-Glu-Leu-Leu-Phe-Pro-Ser-Trp-Glu-Ala-Leu-Phe-Ser-Gly-Ser-Glu-Gly-Pro-Leu-Lys-Pro-Gly-Ala-Arg-Ile-Phe-Ser-Phe-Asp-Gly-Lys-Asp-Val-Leu-Arg-His-Pro-Thr-Trp-Pro-Gln-Lys-Ser-Val-Trp-His-Gly-Ser-Asp-Pro-Asn-Gly-Arg-Arg-Leu-Thr-Glu-Ser-Tyr-Cys-Glu-Thr-Trp-Arg-Thr-Glu-Ala-Pro-Ser-Ala-Thr-Gly-Gln-Ala-Ser-Ser-Leu-Leu-Gly-Gly-Arg-Leu-Leu-Gly-Gln-Ser-Ala-Ala-Ser-Cys-His-His-Ala-Tyr-Ile-Val-Leu-Cys-Ile-Glu-Asn-Ser-Phe-Met-Thr-Ala-Ser (HF-COLL-18/514cf) (SEQ ID NO: 1) or
  - b) an amidated, acetylated, phosphorylated, or glycosylated derivative of the isolated peptide.
79. (New) The isolated peptide of claim 78 consisting of the amino acid sequence Val-Ala-Leu-Asn-Ser-Pro-Leu-Ser-Gly-Gly-Met-Arg-Gly-Ile-Arg-Gly-Ala-Asp-Phe-Gln-Cys-Phe-Gln-

Gln-Ala-Arg-Ala-Val-Gly-Leu-Ala-Gly-Thr-Phe-Arg-Ala-Phe-Leu-Ser-Ser-Arg-Leu-Gln-  
Asp-Leu-Tyr-Ser-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Ile-Val-Asn-Leu-Lys-Asp-  
Glu-Leu-Leu-Phe-Pro-Ser-Trp-Glu-Ala-Leu-Phe-Ser-Gly-Ser-Glu-Gly-Pro-Leu-Lys-Pro-  
Gly-Ala-Arg-Ile-Phe-Ser-Phe-Asp-Gly-Lys-Asp-Val-Leu-Arg-His-Pro-Thr-Trp-Pro-Gln-Lys-  
Ser-Val-Trp-His-Gly-Ser-Asp-Pro-Asn-Gly-Arg-Arg-Leu-Thr-Glu-Ser-Tyr-Cys-Glu-Thr-  
Trp-Arg-Thr-Glu-Ala-Pro-Ser-Ala-Thr-Gly-Gln-Ala-Ser-Ser-Leu-Leu-Gly-Gly-Arg-Leu-  
Leu-Gly-Gln-Ser-Ala-Ala-Ser-Cys-His-His-Ala-Tyr-Ile-Val-Leu-Cys-Ile-Glu-Asn-Ser-Phe-  
Met-Thr-Ala-Ser (HF-COLL-18/514cf) (SEQ ID NO: 1).

80. (New) The isolated peptide of claim 78 consisting of the amidated, acetylated, phosphorylated, or glycosylated derivative of the isolated peptide .
81. (New) In a process for the preparation of a peptide comprising expressing the peptide using a prokaryotic or eukaryotic cell, the improvement wherein the peptide is the isolated peptide according to claim 78.
82. (New) A process for the preparation of isolated peptide according to claim 78 comprising isolating the peptide from human blood, chromatographically.

- 83. (New) A process for the preparation of the isolated peptide according to claim 78 comprising synthesizing the peptide, using solid-phase or liquid-phase synthesis, and purifying the peptide chromatographically.
- 84. (New) A medicament containing the isolated peptide according to claim 78 as the active ingredient in combination with excipients.
- 85. (New) The medicament according to claim 84 in a form for oral administration.
- 86. (New) The medicament according to claim 84 in a form for parenteral, intravenous, or intramuscular administration.
- 87. (New) The medicament according to claim 84 in a form for intracutaneous or intrathecal administration.
- 88. (New) The medicament according to claim 84 in a form for intranasal administration.
- 89. (New) The medicament according to claim 84 in a form for local-topical application.

90. (New) The medicament according to claim 84 in an aerosol form for transpulmonary application.
91. (New) Isolated antibodies obtainable by immunizing animals with the isolated peptide according to claim 78 or obtainable by using hybridoma technology.